帕金森病中多巴胺介导的步骤值任务的改善:对运动和认知功能的临床测量进行验证
Alyson N Moll1, Harrison C Walker2, Noah Rosenblatt3
1Rehabilitation Science, University of Alabama at Birmingham, Birmingham, AL, United States.
Frontiers in human neuroscience
|December 1, 2025
概括
步骤值任务有效地测量了帕金森病患者的动态平衡控制. 这种评估与临床运动和执行功能测量相关,提供了一个全面的评估工具.
科学领域:
- 神经学 神经学
- 生物力学 生物力学
- 运动科学 运动科学
背景情况:
- 帕金森病 (PD) 显著影响动态平衡控制.
- 评估PD的动态平衡对于监测疾病进展和治疗疗效至关重要.
- 基于跑步机的平衡障碍提供了一种标准化的方法来评估动态平衡.
研究的目的:
- 为了验证一个步骤值任务来测量帕金森病患者的动态平衡控制.
- 评估步骤值任务与运动和执行功能的确定的临床测量之间的相关性.
主要方法:
- 39名患有异常性帕金森病的参与者使用一步值任务进行了动态平衡评估.
- 参与者被指示避免在跑步机扰动期间踏步,而步骤值是由扰动大小定义的.
- 通过将药物诱导的步骤值变化与临床评估 (MDS-UPDRS) 和执行功能测试 (CPT-3) 的变化相关联来确定有效性.
主要成果:
- 药物介导的步骤值任务变化与MDS-UPDRS第三部分 (总体运动得分) 和其姿势不稳定性子得分的变化有显著的相关性.
- 阶段值任务还显示了与执行职能指标的显著相关性,包括CPT-3遗漏,委员会和可变性T分数.
- 这些发现表明,步骤值任务捕捉了平衡控制中的药物反应变化.
结论:
- 步骤值任务是评估帕金森病动态平衡控制的验证和可靠措施.
- 它与黄金标准临床评估的相关性凸显了其作为评估PD平衡的运动和执行功能方面综合工具的潜力.
- 这项任务可以帮助客观评估和监测针对帕金森病平衡缺陷的干预措施.
相关概念视频
Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


